Supported by Grants HL-20985 A-2, MO1 RRO1271, and 5 U10 HL-52193-05, from the NIH.
Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial
Version of Record online: 24 NOV 2002
Volume 41, Issue 9, pages 1086–1092, September 2001
How to Cite
Vichinsky, E. P., Luban, N. L.C., Wright, E., Olivieri, N., Driscoll, C., Pegelow, C. H., Adams, R. J. and for the Stroke Prevention Trial in Sickle Cell Anemia (2001), Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion, 41: 1086–1092. doi: 10.1046/j.1537-2995.2001.41091086.x
- Issue online: 24 NOV 2002
- Version of Record online: 24 NOV 2002
- Received: 25 January 2001; Revised: 02 April 2001; Accepted: 04 April 2001
- HTR(s) = hemolytic transfusion reaction(s);
- SCD = sickle cell disease;
- STOP = Stroke Prevention Trial in Sickle Cell Anemia
BACKGROUND: Most sickle cell anemia patients undergo transfusion therapy to prevent complications. The Stroke Prevention Trial in Sickle Cell Anemia showed that transfusion therapy is effective in the primary prevention of stroke. Despite its efficacy, transfusion therapy is limited by alloimmunization. The purpose of this study was to determine if a multicenter trial could implement a transfusion program utilizing phenotypically matched blood to reduce alloimmunization.
STUDY DESIGN AND METHODS: One hundred thirty children underwent RBC phenotyping and antibody screening with review of blood bank records. The protocol required use of WBC-reduced RBCs, which were matched for E, C, and Kell. Monthly alloantibody testing and review of transfusion forms were performed to determine compliance and the occurrence of any adverse events.
RESULTS: Patient RBCs expressed a low frequency of Kell (2%), E (20%), and C (25%) antigens. Sixty-one patients received 1830 units. Ninety-seven percent of all units were WBC reduced. Only 29 units were inadvertently not matched for E, C, and Kell. Five patients (8%) developed a clinically significant alloantibody. Four developed a single antibody to E or Kell. Three patients (5%) developed a warm autoantibody. There were 11 transfusion reactions and 8 transfusion-associated events. Transfusion reactions included 6 febrile reactions (0.33%/unit), 3 allergic (0.16%/unit), and 2 hemolytic (0.11%/unit). Associated events included 4 episodes of hypertension (0.22%/unit), 3 crises (0.16%/unit), and 1 transient ischemic attack (0.05%/unit).
CONCLUSION: This is the first multicenter study to show that extended RBC phenotyping can be implemented nationwide. Compared to studies, the alloimmunization rate dropped from 3 percent to 0.5 percent per unit, and hemolytic transfusion reactions dropped by 90 percent. It is recommended that all transfused sickle cell anemia patients be antigen matched for E, C, and Kell. Patients should be closely monitored during transfusions to avoid preventable risks.